1231P Phase I study to evaluate the safety, tolerability, and efficacy of VCN-01 in combination with durvalumab (MEDI4736) in subjects with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC)

1231P Phase I study to evaluate the safety, tolerability, and efficacy of VCN-01 in combination with durvalumab (MEDI4736) in subjects with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC)

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 33; p. S1112
Main Authors: Jove, M., Brana, I., Oliva Bernal, M., Hernando-Calvo, A., Erasun Lecuona, C., Assaf Pastrana, J.D., Bazan Peregrino, M., Mato-Berciano, A., Maliandi, M.V., Torres-Manjon, S., Martinez de Villareal, J., Real, F.X., Nuciforo, P.G., Alemany, R., Capella, G., Blasi, E., Blasco, C., Cascallo Piqueras, M., Mesia Nin, R.
Format: Journal Article
Language:English
Published: 01-09-2022
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0923-7534
DOI:10.1016/j.annonc.2022.07.1349